EUR 0.71
(-1.8%)
Year | Inventory | Inventory Growth |
---|---|---|
2023 | - EUR | -100.0% |
2022 | 15.97 Million EUR | 1597599900.0% |
2021 | 1.00 EUR | 0.0% |
2020 | 1.00 EUR | -100.0% |
2019 | 2.42 Million EUR | 446.28% |
2018 | 443 Thousand EUR | 64.07% |
2017 | 270 Thousand EUR | 22.17% |
2016 | 221 Thousand EUR | -81.01% |
2015 | 1.16 Million EUR | 1.31% |
2014 | 1.14 Million EUR | 17.85% |
2013 | 975 Thousand EUR | -11.92% |
2012 | 1.1 Million EUR | 1.28% |
2011 | 1.09 Million EUR | 12.45% |
2010 | 972 Thousand EUR | 18.97% |
2009 | 817 Thousand EUR | 37.31% |
2008 | 595 Thousand EUR | 7337.5% |
2007 | 8000.00 EUR | -98.17% |
2006 | 437 Thousand EUR | 0.0% |
2004 | 274 Thousand EUR | 3.4% |
2003 | 265 Thousand EUR | 43.24% |
2002 | 185 Thousand EUR | -12.74% |
2001 | 212 Thousand EUR | -14.17% |
2000 | 247 Thousand EUR | 49.7% |
1999 | 165 Thousand EUR | -3.12% |
1998 | 170.31 Thousand EUR | -7.37% |
1997 | 183.86 Thousand EUR | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2024 Q2 | - EUR | 0.0% |
2023 Q1 | - EUR | -100.0% |
2023 Q4 | - EUR | 0.0% |
2023 Q2 | 2.08 Million EUR | 0.0% |
2023 Q3 | - EUR | -100.0% |
2023 FY | - EUR | -100.0% |
2022 Q3 | - EUR | -100.0% |
2022 FY | 15.97 Million EUR | 1597599900.0% |
2022 Q4 | 15.97 Million EUR | 0.0% |
2022 Q2 | 2.71 Million EUR | 270999900.0% |
2022 Q1 | 1.00 EUR | -100.0% |
2021 Q2 | 20.73 Million EUR | 2073299900.0% |
2021 FY | 1.00 EUR | 0.0% |
2021 Q1 | 1.00 EUR | -100.0% |
2021 Q3 | 1.00 EUR | -100.0% |
2021 Q4 | 2.51 Million EUR | 250999900.0% |
2020 Q1 | - EUR | -100.0% |
2020 Q2 | 23.04 Million EUR | 0.0% |
2020 Q3 | 1.00 EUR | -100.0% |
2020 FY | 1.00 EUR | -100.0% |
2020 Q4 | 2.63 Million EUR | 263699900.0% |
2019 Q2 | 418 Thousand EUR | 0.0% |
2019 FY | 2.42 Million EUR | 446.28% |
2019 Q3 | - EUR | -100.0% |
2019 Q4 | 2.42 Million EUR | 0.0% |
2019 Q1 | 418 Thousand EUR | -5.64% |
2018 FY | 443 Thousand EUR | 64.07% |
2018 Q2 | 314 Thousand EUR | 0.0% |
2018 Q1 | 314 Thousand EUR | 16.3% |
2018 Q4 | 443 Thousand EUR | 0.0% |
2018 Q3 | 443 Thousand EUR | 41.08% |
2017 Q4 | 270 Thousand EUR | 0.0% |
2017 Q2 | 194 Thousand EUR | 0.0% |
2017 FY | 270 Thousand EUR | 22.17% |
2017 Q3 | 270 Thousand EUR | 39.18% |
2017 Q1 | 194 Thousand EUR | -12.22% |
2016 FY | 221 Thousand EUR | -81.01% |
2016 Q3 | 221 Thousand EUR | 46.36% |
2016 Q2 | 151 Thousand EUR | 0.0% |
2016 Q1 | 151 Thousand EUR | -87.03% |
2016 Q4 | 221 Thousand EUR | 0.0% |
2015 Q2 | 1.13 Million EUR | 0.0% |
2015 FY | 1.16 Million EUR | 1.31% |
2015 Q4 | 1.16 Million EUR | 0.0% |
2015 Q3 | 1.16 Million EUR | 2.37% |
2015 Q1 | 1.13 Million EUR | -1.04% |
2014 Q4 | 1.14 Million EUR | 0.0% |
2014 Q3 | 1.14 Million EUR | -2.3% |
2014 FY | 1.14 Million EUR | 17.85% |
2014 Q2 | 1.17 Million EUR | 0.0% |
2014 Q1 | 1.17 Million EUR | 20.62% |
2013 Q1 | 897 Thousand EUR | -18.97% |
2013 FY | 975 Thousand EUR | -11.92% |
2013 Q4 | 975 Thousand EUR | 0.0% |
2013 Q3 | 975 Thousand EUR | 8.7% |
2013 Q2 | 897 Thousand EUR | 0.0% |
2012 FY | 1.1 Million EUR | 1.28% |
2012 Q4 | 1.1 Million EUR | 0.0% |
2012 Q2 | 1.17 Million EUR | 0.0% |
2012 Q3 | 1.1 Million EUR | -5.79% |
2011 Q2 | 1.03 Million EUR | 0.0% |
2011 Q4 | 1.09 Million EUR | 0.0% |
2011 FY | 1.09 Million EUR | 12.45% |
2010 FY | 972 Thousand EUR | 18.97% |
2010 Q2 | 785 Thousand EUR | 0.0% |
2010 Q4 | 972 Thousand EUR | 0.0% |
2009 Q2 | 921 Thousand EUR | 0.0% |
2009 FY | 817 Thousand EUR | 37.31% |
2009 Q4 | 817 Thousand EUR | 0.0% |
2008 FY | 595 Thousand EUR | 7337.5% |
2008 Q4 | 595 Thousand EUR | 0.0% |
2007 FY | 8000.00 EUR | -98.17% |
2006 FY | 437 Thousand EUR | 0.0% |
2005 Q2 | - EUR | 0.0% |
2004 FY | 274 Thousand EUR | 3.4% |
2004 Q4 | 274 Thousand EUR | 0.0% |
2004 Q2 | - EUR | 0.0% |
2004 Q1 | - EUR | -100.0% |
2003 Q3 | - EUR | 0.0% |
2003 Q4 | 265 Thousand EUR | 0.0% |
2003 Q2 | - EUR | 0.0% |
2003 FY | 265 Thousand EUR | 43.24% |
2003 Q1 | - EUR | -100.0% |
2002 Q4 | 185 Thousand EUR | 0.0% |
2002 Q2 | - EUR | 0.0% |
2002 Q1 | - EUR | -100.0% |
2002 FY | 185 Thousand EUR | -12.74% |
2002 Q3 | - EUR | 0.0% |
2001 Q3 | - EUR | 0.0% |
2001 Q4 | 212 Thousand EUR | 0.0% |
2001 FY | 212 Thousand EUR | -14.17% |
2001 Q1 | - EUR | -100.0% |
2001 Q2 | - EUR | 0.0% |
2000 Q1 | - EUR | -100.0% |
2000 FY | 247 Thousand EUR | 49.7% |
2000 Q3 | - EUR | 0.0% |
2000 Q4 | 247 Thousand EUR | 0.0% |
2000 Q2 | - EUR | 0.0% |
1999 FY | 165 Thousand EUR | -3.12% |
1999 Q4 | 165 Thousand EUR | 0.0% |
1998 FY | 170.31 Thousand EUR | -7.37% |
1998 Q4 | 170.31 Thousand EUR | 0.0% |
1997 FY | 183.86 Thousand EUR | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
ABIONYX Pharma SA | 221 Thousand EUR | 100.0% |
ABIVAX Société Anonyme | 1.00 EUR | 100.0% |
Adocia SA | 272 Thousand EUR | 100.0% |
Aelis Farma SA | 53 Thousand EUR | 100.0% |
Biophytis S.A. | - EUR | NaN% |
Advicenne S.A. | 1.74 Million EUR | 100.0% |
genOway Société anonyme | 982.75 Thousand EUR | 100.0% |
IntegraGen SA | 311.44 Thousand EUR | 100.0% |
Medesis Pharma S.A. | 164.62 Thousand EUR | 100.0% |
Neovacs S.A. | - EUR | NaN% |
NFL Biosciences SA | -1.1 Million EUR | 100.0% |
Plant Advanced Technologies SA | 1.22 Million EUR | 100.0% |
Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 100.0% |
Sensorion SA | - EUR | NaN% |
Theranexus Société Anonyme | - EUR | NaN% |
TME Pharma N.V. | 91 Thousand EUR | 100.0% |
Valbiotis SA | 1 Million EUR | 100.0% |
TheraVet SA | 123.34 Thousand EUR | 100.0% |
Valerio Therapeutics Société anonyme | 1.00 EUR | 100.0% |
argenx SE | 281.12 Million EUR | 100.0% |
BioSenic S.A. | - EUR | NaN% |
Celyad Oncology SA | 1.26 Million EUR | 100.0% |
DBV Technologies S.A. | 1.00 USD | 100.0% |
Galapagos NV | 73.97 Million EUR | 100.0% |
Genfit S.A. | 4000.00 EUR | 100.0% |
GeNeuro SA | - EUR | NaN% |
Hyloris Pharmaceuticals SA | 1.00 EUR | 100.0% |
Innate Pharma S.A. | 1.00 EUR | 100.0% |
Inventiva S.A. | 417 Thousand EUR | 100.0% |
MaaT Pharma SA | 190 Thousand EUR | 100.0% |
MedinCell S.A. | -6.71 Million EUR | 100.0% |
Nanobiotix S.A. | 200 Thousand EUR | 100.0% |
Onward Medical N.V. | 936 Thousand EUR | 100.0% |
Oryzon Genomics S.A. | 6029.00 EUR | 100.0% |
OSE Immunotherapeutics SA | - EUR | NaN% |
Oxurion NV | 128 Thousand EUR | 100.0% |
Pharming Group N.V. | 51.38 Million EUR | 100.0% |
Poxel S.A. | 2.95 Million EUR | 100.0% |
GenSight Biologics S.A. | 1.00 EUR | 100.0% |
Financière de Tubize SA | - EUR | NaN% |
UCB SA | 1.03 Billion EUR | 100.0% |
Valneva SE | 44.46 Million EUR | 100.0% |
Vivoryon Therapeutics N.V. | 1.00 EUR | 100.0% |